November 6, 2026 | OTCQB: MEDIF | TSX: LABS
MediPharm Labs Corp. has reached a significant milestone in its international expansion strategy after securing a positive European regulatory opinion for its proprietary metered-dose cannabis inhaler platform, potentially opening the door to commercialization in the United Kingdom and selected European markets in 2027.
The announcement, made November 5, comes at an important moment for the Canadian pharmaceutical cannabis company, which has recently reported improved financial performance, expanded its international distribution network and appointed Greg Hunter as permanent chief executive officer.
The positive opinion from BSI Group confirms that the inhaler’s device component satisfies applicable European safety, performance and design requirements under the Article 117 regulatory framework. Although additional country-specific authorizations and import permits remain necessary, the development removes an important regulatory obstacle from MediPharm’s proposed European launch.
Unlike traditional cannabis products, the inhaler is designed to deliver a precise, repeatable cannabinoid dose through a familiar pharmaceutical delivery system. MediPharm has already introduced versions of the platform in Canada and Australia, and its planned European portfolio includes THC and balanced THC-CBD formulations.
The company expects Blackpoint Limited to lead distribution and commercialization in the United Kingdom and Europe, while MediPharm remains the exclusive global manufacturer and licensee of the technology under its 2024 agreement with Remidose Aerosols.
The European milestone follows an October expansion into Panama, where MediPharm completed its first commercial shipment of CBD metered-dose inhalers to Adeiwa Pharma. The company said the shipment marked its first sale into Panama and extended its international footprint to more than ten countries and regions.
That geographic reach matters because medical cannabis markets operate under differing regulatory frameworks. The ability to manufacture standardized products and navigate import and distribution requirements could help MediPharm pursue business across multiple jurisdictions, although approvals and market adoption are far from assured.
MediPharm’s recent financial performance provides another part of the story. In its second-quarter 2026 results, the company reported revenue of $10 million, up 11% from the preceding quarter, and adjusted EBITDA of approximately $900,000. The company also reported positive quarterly net income, a 43.2% gross margin and approximately $9.9 million in cash.
International medical revenue accounted for $5.8 million of the quarter’s total, according to the company, while sales in Germany increased 45% sequentially. Operating expenses fell 44% from the year-earlier quarter, reflecting cost-reduction measures. Adjusted EBITDA is a non-IFRS measure and should not be confused with net income or operating cash flow.
The management transition adds another dimension to the company’s next chapter. On November 4, MediPharm named Greg Hunter chief executive officer and a director after he had served as interim CEO since January. Hunter, who joined the company as chief financial officer in 2021, will continue overseeing finance until a successor is appointed.
The appointment provides continuity at a time when MediPharm is seeking to turn its pharmaceutical manufacturing capabilities into a broader commercial platform. Its operations include cannabinoid active pharmaceutical ingredients, purified concentrates and precision-dosed products for regulated medical markets.
Looking ahead, the inhaler’s planned 2027 entry into the United Kingdom and selected European markets will be a key test of the strategy. MediPharm and its partners must still satisfy local regulatory, import, prescribing and distribution requirements, while competing for the attention of physicians, patients and healthcare distributors.
The company’s improving quarterly figures are encouraging, but a single profitable quarter does not guarantee sustained earnings. Regulatory delays, manufacturing costs, reimbursement changes, competition and the pace of commercial adoption could affect results.
For investors following OTCQB-listed MEDIF, the latest European regulatory milestone offers a concrete development to watch rather than a promise of future sales. If MediPharm can translate its manufacturing expertise, international relationships and new inhaler platform into recurring demand, the company may strengthen its position in the evolving pharmaceutical cannabinoid market.
For now, the story is one of measurable progress paired with meaningful execution risk: a company seeking to move beyond cannabis supply into a more standardized, internationally distributed pharmaceutical delivery business.
Sources: MediPharm Labs announcements dated November 5, November 4, October 13 and August 13, 2026. https://medipharmlabs.com/news
Disclaimer: For informational purposes only; not investment advice. Company-reported financial and operational information should be reviewed alongside regulatory filings. Forward-looking statements are subject to risk.
Deja un comentario